Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Clinical trial NCT04745832 · TERMINATED

Trial details

NCT number: NCT04745832
Sponsor: MEI Pharma, Inc.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Follicular Lymphoma (FL)Non Hodgkin Lymphoma Marginal Zone Lymphoma

Start date: 2021-08-13
Primary completion: 2023-03-20
Enrollment: 82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.